Novo Nordisk Annual Report 2021
Contents Introducing Novo Nordisk
Strategic Aspirations
Key risks Management
Consolidated statements
Additional information
Novo Nordisk Annual Report 2021 50
Income statement
and statement of comprehensive income for the year ended 31 December
DKK million
Income statement
Note
2021
2020
2019
DKK million
Note
2021
2020
2019
Statement of comprehensive income
Net sales
Cost of goods sold
Gross profit
2.1, 2.2
2.2
Sales and distribution costs
Research and development costs
Administrative costs
2.2
2.2, 2.3
2.2
Other operating income and expenses
2.2, 2.5
140,800
(23,658)
117,142
(37,008)
(17,772)
(4,050)
332
126,946 122,021
(20,932) (20,088)
106,014 101,933
Net profit
47,757
42,138
38,951
Other comprehensive income:
Operating profit
58,644
Financial income
4.10
Financial expenses
4.10
Profit before income taxes
Income taxes
2.6
Net profit
2,887
(2,451)
59,080
(11,323)
47,757
54,126
1,628
(2,624) (3,995)
53,130 48,553
(10,992) (9,602)
42,138 38,951
(32,928) (31,823)
(15,462) (14,220)
(3,958) (4,007)
460
600
52,483
Items that will not be reclassified subsequently to the income statement:
Remeasurements of retirement benefit obligations
146
(67)
(187)
Items that will be reclassified subsequently to the income statement:
Exchange rate adjustments of investments in subsidiaries
Cash flow hedges:
1,624
(1,689)
226
65
Realisation of previously deferred (gains)/losses
Deferred gains/(losses) incurred during the period
4.2, 4.4
(1,802)
329
1,677
4.2, 4.4
(1,755)
1,384
(329)
Other items
112
10
9
Tax on other comprehensive income, income/(expense)
Other comprehensive income, net of tax
2.6
1,005
(577)
(231)
(670)
(610)
1,165
Total comprehensive income
47,087
41,528 40,116
Earnings per share
Basic earnings per share (DKK)
2.7
20.79
18.05
16.41
Diluted earnings per share (DKK)
2.7
20.74
18.01
16.38View entire presentation